Otto Sticher, Professor of Pharmacognosy and Pharmaceutical Biology Emeritus at the ETH Zürich (Switzerland), died unexpectedly and peacefully on March 11 at his home in Ebmatingen, Switzerland. He was 85.
Limulus Amebocyte Lysate Market Still Has Room To Grow: Fuzhou Xinbei, Accumedi Solutions, Lonza Group
iCrowd Newswire
The Latest Released Limulus Amebocyte Lysate market study has evaluated the future growth potential of
Global
Limulus Amebocyte Lysate market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Limulus Amebocyte Lysate market. The study includes market share analysis and profiles of players such as Lonza Group AG (Switzerland), Charles River Laboratories, Inc. (United States), ASSOCIATES OF CAPE COD, INC. (United States), Accumedi Solutions Co., Ltd. (China), Xiamen Bioendo Technology (China), Zhan
Apply for a licence to market a medicine in the UK
How to license a medicine for sale in the UK, including applications through national and international routes.
From: Contents
Print this page
This guidance also covers licensing a medicine in Northern Ireland through the centralised, decentralised and mutual recognition European procedures.
Which procedure to follow
There are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotland and Wales) or Northern Ireland. The options available will be determined by the intended market and the type of application. The markets in which each route is applicable are indicated in the following guidance: